Antibody-Drug Conjugates in Targeted Therapy for Cancer
- Authors: Ruoping Tang1, Simy Cohen2, Ollivier Legrand3, Jean-Pierre Marie4
-
View Affiliations Hide Affiliations1 Universit Pierre et Marie Curie; INSERM UMRs 736; Assistance Publique Hpitaux de Paris; Hpital Htel Dieu, 1 place du Parvis de Notre-Dame, 75181 Paris cedex 04, France 2 Universit Pierre et Marie Curie; INSERM UMRs 736; Assistance Publique Hpitaux de Paris; Hpital Htel Dieu, 1 place du Parvis de Notre-Dame, 75181 Paris cedex 04, France 3 Universit Pierre et Marie Curie; INSERM UMRs 736; Assistance Publique Hpitaux de Paris; Hpital Htel Dieu, 1 place du Parvis de Notre-Dame, 75181 Paris cedex 04, France 4 Universit Pierre et Marie Curie; INSERM UMRs 736; Assistance Publique Hpitaux de Paris; Hpital Htel Dieu, 1 place du Parvis de Notre-Dame, 75181 Paris cedex 04, France
- Source: Frontiers in Drug Design and Discovery: Volume 3 , pp 525-537
- Publication Date: January 2007
- Language: English
Antibody-Drug Conjugates in Targeted Therapy for Cancer, Page 1 of 1
< Previous page | Next page > /docserver/preview/fulltext/9781608052011/chapter-20-1.gif
An antibody-drug conjugate consists of a potent cytotoxic drug attached to a monoclonal antibody specially targeted on cancer associated antigen. The antigen targeted chemotherapy can improve therapeutic index by increasing potential efficacy and decreasing systemic toxicity. In this review, we described the study and the progress in antibody engineering, the process of drug selection, and the development of linker to optimize the clinical trials. We also discussed about the possible mechanism of cell death induced by an antibody- drug conjugate and the potential resistance to an antibody-drug conjugate. Nonetheless, the successful results from Gentuzumab ozogamicin and other encouraging clinical trials will continue to drive the preclinical development of antibody-drug conjugates.
-
From This Site
/content/books/9781608052011.chapter-20dcterms_subject,pub_keyword-contentType:Journal -contentType:Figure -contentType:Table -contentType:SupplementaryData105
